Supplementary Material for: Effect of Bilastine on Chronic Urticaria: A Systematic Review and Meta-Analysis

<b><i>Background:</i></b> Allergic diseases are a public health problem with the largest number of patients and the widest age distribution. Chronic urticaria (CU) is a common clinical allergic disease. Bilastine is effective in the treatment of CU, especially skin wind masses and erythema. The purpose of this study was to systematically evaluate the efficacy and safety of Bilastine in the treatment of CU symptoms and to provide an evidence-based reference for clinical rational drug use. <b><i>Methods:</i></b> PubMed, Scopus, the Cochrane Library, Embase, EBSCO, and other databases were searched by computer to collect the trials on the effect of bilastine on patients with CU. The retrieval time limit was established until November 2021. Two researchers independently screened the literature, extracted data, and evaluated the risk of bias in the included study. Meta-analysis was performed using RevMan5.4 software. <b><i>Results:</i></b> A total of 7 studies were included, including 975 patients. Meta-analysis results showed that compared to the control group, bilastine significantly improved the skin quality of life index, Total Symptom Score (TSS), and weekly urticaria activity score. The skin quality of life index DLQI score (MD = −4.98, 95% CI: −8.09 to −1.86, <i>p</i> = 0.002), skin symptom score TSS (MD = −1.62, 95% CI −2.29 to −0.94, <i>p</i> &lt; 0.00001), the number of hives in a week UAS-7 score (MD = −25.28, 95% CI −32.36 to −18.19, <i>p</i> &lt; 0.00001), and the differences were statistically significant. <b><i>Conclusions:</i></b> Bilastine has a better therapeutic effect on CU and can also significantly improve the clinical symptoms and quality of life of CU.

<b><i>背景：</i></b> 过敏性疾病是患病人数最多、年龄分布最广的公共卫生问题。慢性荨麻疹（Chronic urticaria, CU）是临床常见的过敏性疾病。比拉斯汀（Bilastine）对慢性荨麻疹具有良好的治疗效果，尤其针对皮肤风团与红斑。本研究旨在系统评价比拉斯汀治疗慢性荨麻疹症状的疗效与安全性，为临床合理用药提供循证参考。<b><i>方法：</i></b> 通过计算机检索PubMed、Scopus、考克兰图书馆（Cochrane Library）、Embase、EBSCO等数据库，收集比拉斯汀治疗慢性荨麻疹患者的相关临床试验，检索时限截至2021年11月。由2名研究者独立筛选文献、提取数据并评价纳入研究的偏倚风险，采用RevMan5.4软件进行Meta分析。<b><i>结果：</i></b> 共纳入7项研究，涉及975例患者。Meta分析结果显示，与对照组相比，比拉斯汀可显著改善皮肤病生活质量指数（Dermatology Life Quality Index, DLQI）、总症状评分（Total Symptom Score, TSS）以及每周荨麻疹活动度评分。其中皮肤病生活质量指数DLQI评分（MD=-4.98，95%CI：-8.09~-1.86，<i>p</i>=0.002）、皮肤症状总评分TSS（MD=-1.62，95%CI：-2.29~-0.94，<i>p</i>&lt;0.00001）、每周荨麻疹活动度评分7项（Urticaria Activity Score 7, UAS-7）（MD=-25.28，95%CI：-32.36~-18.19，<i>p</i>&lt;0.00001），差异均具有统计学意义。<b><i>结论：</i></b> 比拉斯汀治疗慢性荨麻疹疗效更佳，可显著改善慢性荨麻疹患者的临床症状与生活质量。